TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06200324

Intervention type: OTHER
Intervention: Ready-to-Use Parenteral Nutrition
Description: In newborns weighing less than 1000 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum volume of 128 ml/kg/day, with a provision of 4 grams/kg/day of protein and a metabolic rate of 12 mg/kg/minute.~For newborns weighing between 1001-1500 grams, parenteral nutrition is initiated at volumes of 70-80 ml/kg/day up to a maximum of 110 ml/kg/day.~When enteral intake exceeds 70 ml/kg/day, a gradual decrease in the volume of parenteral nutrition is initiated. We discontinue parenteral nutrition in newborns weighing less than 1000 grams with enteral volume of 120 ml/kg/day, and for those between 1000 grams and 1500 grams, enteral nutrition volume of 100 ml/kg/day.
Study: NCT02727751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Study: NCT02374801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SonR automatic optimization feature turned ON (AV+VV).
Study: NCT05007899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Alternate day dosing of ferrous sulfate
Study: NCT04595461

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard patient education with verbal and written education
Study: NCT01082575

Intervention type: DEVICE
Intervention: Oxygen Monitoring
Description: No intervention
Study: NCT01959854

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose
Description: 0.25% carboxymethylcellulose preservative free

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: xanthan gum
Description: 0.2% xanthan gum preservative free
Study: NCT01557036

Intervention type: DEVICE
Intervention: Pipeline Embolization Device
Description: Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
Study: NCT03124017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
Study: NCT01629589

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)
Description: 0.5 mL, Intramuscular
Study: NCT02336958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermediate cervical plexus block ropivacaine
Description: 20ml ultrasound guided intermediate cervical plexus block.
Study: NCT00151346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Fentanyl (for CSE)
Description: Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine and Fentanyl (for traditional epidural)
Description: Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
Study: NCT03545230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: :Four Not Techniques
Description: :Four Not Techniques~1. Not enter posteriorly~2. Not too much dissection the muscle around the lateral condyle during surgery~3. Not perfect anatomical reduction~4. Not using bone graft.
Study: NCT02675569

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter
Description: A method of vascular access for hemodialysis that all participants will have in place prior to randomization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistula
Description: A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
Study: NCT00927394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 160 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 160 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 150 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Aliskiren
Description: Placebo for Aliskiren 150 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Valsartan
Description: Placebo for Valsartan 160 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Valsartan
Description: Placebo for Valsartan 160 mg capsules
Study: NCT04400032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Description: The Mesenchymal Stromal Cells will be administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Description: The Mesenchymal Stromal Cells will be administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Description: The Mesenchymal Stromal Cells will be administered intravenously
Study: NCT03878771

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin gel in Orabase
Description: applied on oral mucositis and /or ulcer 3 times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dermovate cream in Orabase
Description: applied on oral mucositis and /or ulcer 3 times per day
Study: NCT01221363

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life style intervention
Description: Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
Study: NCT02517463

Intervention type: DRUG
Intervention: Ulipristal acetate
Description: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.

Intervention type: DRUG
Intervention: Ulipristal acetate
Description: This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
Study: NCT03476733

Intervention type: OTHER
Intervention: Detection of drug related problem in inpatient
Description: Detection of drug related problem in inpatient

Intervention type: OTHER
Intervention: Detection of drug related problem in inpatient
Description: Detection of drug related problem in inpatient
Study: NCT01405014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hold Me Tight
Description: Relationship enhancement group
Study: NCT00394277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1400-1600 mg po daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1400-1600 mg po daily for 48 weeks
Study: NCT03510026

Intervention type: DEVICE
Group type: OTHER
Intervention: Low thermal device preparation
Description: One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
Study: NCT04332887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Exercise Program
Description: Patients in the experimental group will receive a 12-week multidimensional exercise program; patients in the control group will maintain their usual life activities.
Study: NCT03127683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral position
Description: The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension
Description: The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexion
Description: The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rotation
Description: The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain TM
Description: Single Use Laryngeal Mask Sterile
Study: NCT02336958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intermediate cervical plexus block ropivacaine
Description: 20ml ultrasound guided intermediate cervical plexus block.
Study: NCT01382654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine 0.1%
Description: nasal spray 2 sprays to each nostril for a total of 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine 0.1% with taste masking agent
Description: nasal spray 2 sprays to each nostril for a total for a 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine 0.2%
Description: nasal spray 2 sprays to each nostril for a total of 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinastine 0.2% with taste masking agent
Description: nasal spray 2 sprays to each nostril for a total of 3 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azelastine 0.1%
Description: nasal spray 2 sprays to each nostril for a total of 3 doses
Study: NCT00522561

Intervention type: OTHER
Group type: OTHER
Intervention: energetic and non invasive limb mechanical measurements
Description: Force velocity stiffness running
Study: NCT03928730

Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection and removal
Description: Surgical resection or removal for histopathological examination

Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection and removal
Description: Surgical resection or removal for histopathological examination

Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection and removal
Description: Surgical resection or removal for histopathological examination

Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection and removal
Description: Surgical resection or removal for histopathological examination

Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection and removal
Description: Surgical resection or removal for histopathological examination
Study: NCT00720252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
Study: NCT03574948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HTP
Description: 8 weeks active substance 5-HTP (2 x 100mg per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 8 weeks placebo (2 x 1 caps per day)
Study: NCT02119429

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pumpkin Seed Oil
Description: 2 grams per day, everyday for 12 weeks.
Study: NCT02336958

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pericarotidal infiltration (active comparator) ropivacaine
Description: 5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: jugular infiltration prilocaine
Description: 5ml prilocaine 1% jugular infiltration for wound drainage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: jugular infiltration prilocaine
Description: 5ml prilocaine 1% jugular infiltration for wound drainage.
Study: NCT02119429

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Germ Oil
Description: 2 grams per day, everyday for 12 weeks.
Study: NCT04150237

Intervention type: OTHER
Intervention: Simulation training in gastroscopy
Description: Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
Study: NCT02336958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pericarotidal infiltration (placebo comparator) saline
Description: 5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
Study: NCT04185181

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality
Description: wii video game based exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: proprioceptive neuromuscular facilitation
Description: PNF with breathing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complete decogestive therapy
Description: pneumatic compression, manual lymph drainage, skin care and home exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: complete decogestive therapy
Description: pneumatic compression, manual lymph drainage, skin care and home exercise program
Study: NCT01834846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-touch
Description: The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
Study: NCT02974322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Description: GED-0301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Description: GED-0301

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03277404

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root canal treatment with smear layer removal
Description: Canal were irrigated with Naocl and EDTA to remove smear layer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment without smear layer removal
Description: only sodium hypochlorite was used for irrigation
Study: NCT00603954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conditioning regimen: TBI + Fludarabine
Description: 2 Gy TBI, Fludarabine 90 mg/m²
Study: NCT04139629

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: antichlamydial antibody test
Description: At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: antichlamydial antibody test
Description: At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.

Intervention type: DRUG
Group type: OTHER
Intervention: treatment of infertility with ART
Description: COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.

Intervention type: DRUG
Group type: OTHER
Intervention: treatment of infertility with ART
Description: COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
Study: NCT00654394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT04139772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate or Enzalutamide
Description: Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.
Study: NCT03025516

Intervention type: DEVICE
Intervention: Rapid Biosensor Systems (RBS) TB Breathalyser
Description: Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.

Intervention type: DEVICE
Intervention: eNose AeonoseTM
Description: The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
Study: NCT01097434

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodegradable polymer limus-eluting stents
Description: due randomization biodegradable polymer limus-eluting stents will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent polymer limus-eluting stent
Description: due randomization permanent polymer limus-eluting stent will be implanted
Study: NCT02136316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7962
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7962
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7962
Description: Oral
Study: NCT00603954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conditioning regimen:TLI (8 Gy) + ATG
Description: TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
Study: NCT01747707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT04150237

Intervention type: OTHER
Intervention: Simulation training in gastroscopy
Description: Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.

Intervention type: OTHER
Intervention: Simulation training in gastroscopy
Description: Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
Study: NCT04176874

Intervention type: PROCEDURE
Intervention: Robotic-assisted diastasis of the rectus abdominis muscles repair
Description: Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
Study: NCT02899455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0904 Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0816 Placebo
Study: NCT04636840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space From Body and Eating Concerns- Teen
Description: Mobile application with coaching component
Study: NCT00338728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study: NCT03207243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3772847
Description: GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol
Description: FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate/salmeterol
Description: FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate
Description: FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
Study: NCT05823324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic play group
Description: The dramatization method with teddy bear, one of the TP methods, was applied during the PIVC intervention
Study: NCT01747707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1